Fresh commentary on Immatics (NasdaqCM:IMTX) highlights its evolution into a broader PRAME-focused oncology platform with multiple monetization paths, alongside reassurance that existing cash resources are expected to support operations into 2028.

Immatics shares recently traded at US$9.52, with a 1-day share price return of 4.73% and 7-day share price return of 7.33%. Over longer periods, the 30-day share price return is down 10.36% and the year-to-date share price return is down 8.90%. Against that backdrop, the 1-year total shareholder return of 62.73%, alongside weaker 3-year and 5-year total shareholder returns, indicates that more recent momentum has followed a tougher multi-year period as investors reassess growth prospects and risks.

If this kind of move in Immatics has caught your attention, it could be a good moment to look across other healthcare-focused AI opportunities using our 40 healthcare AI stocks

With Immatics shifting toward a broader PRAME-focused platform, a 62.73% 1-year total return and operations funded into 2028, investors now face a key question: is the stock still undervalued or is it already pricing in future growth?

Preferred Price-to-Sales Multiple of 30.4x: Is It Justified?

To get a feel for where Immatics stock sits today, it helps to look at how the market prices its current revenue. On a P/S basis, Immatics trades at 30.4x, which is high in absolute terms and lines up with a company that is still in the clinical stage and loss making.

The P/S ratio compares the company’s market value with its revenue, so a higher multiple usually reflects investors placing a premium on future sales potential rather than current profitability. For Immatics, this is particularly relevant because the business is focused on T cell redirecting immunotherapies, reports revenue of €37.3m and a net loss of €214.4m, and is forecast to remain unprofitable over the next 3 years while revenue is expected to grow quickly.

Relative to the broader US Biotechs industry, Immatics trades at a much richer level, with its 30.4x P/S ratio described as expensive versus the industry average of 10.3x. Compared with a peer group average P/S of 31.2x, however, Immatics is described as good value, suggesting the market is pricing it broadly in line with closer comparables, and well above an estimated fair P/S ratio of 0x that indicates the current multiple is far above the level our fair ratio model could move toward.

Result: Price-to-sales of 30.4x (OVERVALUED).

However, Immatics still carries clear risks, including clinical trial setbacks across its PRAME-focused pipeline and the possibility that high P/S expectations reset if sentiment weakens.

Next Steps

If this mix of enthusiasm and caution around Immatics resonates with you, now is a useful time to review the underlying data yourself and weigh both sides using our 1 key reward and 1 important warning sign

Looking for more investment ideas beyond Immatics?

If Immatics has sharpened your focus on opportunity and risk, do not stop here. Broaden your watchlist now before the next wave of ideas moves without you.

• Spot potential turnarounds early by scanning 24 elite penny stocks with strong financials that pair smaller market sizes with stronger fundamentals than many investors expect.
• Target quality at a sensible price by using the 48 high quality undervalued stocks and see which stocks combine robust balance sheets with appealing valuations.
• Prioritise resilience by reviewing the 65 resilient stocks with low risk scores that highlight companies with steadier risk profiles if you want fewer surprises in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.